Prostate Cell News Volume 16.18 | Sep 26 2025

    0
    42







    2025-09-26 | PCN 16.18


    Prostate Cell News by STEMCELL Technologies
    Vol. 16.18 – 26 September, 2025
    TOP STORY

    A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP Inhibition

    Investigators developed a peptide-based proteolysis-targeting chimera (PROTAC) drug that specifically targets BRCA2, leading to its degradation in a DDB1-dependent manner.
    [Cancer Research]

    Abstract
    Scientific resources to support your cancer research. Learn More!
    PUBLICATIONSListed by the impact factor of the journal

    TRIM24-Mediated K27-Linked Ubiquitination of ULK1 Alleviates Energy Stress-Induced Autophagy and Promote Prostate Cancer Growth in the Context of SPOP Mutation

    Scientists demonstrated that ULK1 expression is positively correlated with both loss-of-function mutations in SPOP and the upregulation of the E3 ubiquitin ligase TRIM24 in human prostate cancer specimens.
    [Cell Death & Differentiation]

    Abstract

    Induction of Ferroptosis in Prostate Cancer by CCDC719-13 via TRIM21-Mediated Ubiquitination of SLC7A11

    Researchers revealed that CCDC719-13 expression is markedly reduced in advanced and recurrent prostate cancer, where its low levels serve as an independent predictor of poor prognosis.
    [Cell Death & Differentiation]

    Full ArticleGraphical Abstract

    KBTBD11 Loss Promotes AKT Hyperactivation and Therapeutic Vulnerability in Prostate Cancer

    Scientists demonstrated that KBTBD11 E3 ubiquitin ligase gene is frequently deleted in human prostate cancers and that KBTBD11 loss augments AKT phosphorylation in prostate cancer cells in culture and in patient samples.
    [Oncogene]

    Full ArticleGraphical Abstract

    Characterization of the Immune Landscape in Healthy Mouse Prostate and during Prostate Cancer Progression

    Using scRNA-sequencing and multiparametric flow-cytometry analysis, researchers comprehensively characterized immune cells in wild-type and PTEN(i)pe−/− mouse prostates, a model that closely recapitulates human prostate cancer.
    [Oncoimmunology]

    Full Article

    MIF Facilitates Resistance to Androgen Deprivation Therapy by Regulating AMPD2 Expression in Prostate Cancer Cells

    Investigators demonstrated that androgen deprivation therapy (ADT) induces macrophage migration inhibitory factor (MIF) upregulation, which in turn drives prostate cancer cell proliferation via upregulating AMPD2 expression, eventually contributing to the development of resistance to ADT.
    [The Prostate]

    Abstract
    Learn how to be a great STEM mentor to new lab members
    REVIEWS

    Evolving Roles for the Androgen Receptor and Its Protein Interactome in Castration-Resistant Prostate Cancer

    Less traditional transcriptional roles for androgen receptor (AR), such as those impacting non-coding RNAs as well as transcription-independent roles that include AR-dependent splicing programs and translation control have been recognized to contribute to aggressive CRPC features and treatment resistance.
    [Oncogene]

    Full Article

    Defining Aging-Associated Factors That Increase Susceptibility to Prostate Cancer

    The authors take a broad view of both prostate epithelial cell-intrinsic and cell-extrinsic factors that change with age and are likely to contribute to age-related risk of prostate tumorigenesis. For each factor, they discuss the impact of these age-related changes on cancer risk.
    [Endocrine-Related Cancer]

    Abstract
    INDUSTRY AND POLICY NEWS

    NRG Oncology PREDICT-RT Study Completes Patient Accrual, Tests Individualized Concurrent Therapy and Radiation for High-Risk Prostate Cancer

    The NRG Oncology study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial’s anticipated accrual completion date.
    [NRG Oncology]

    Press Release

    FibroGen Initiates Phase II Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

    FibroGen, Inc. announced the initiation of the Phase II monotherapy, dose-optimization trial of FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46-expressing cancer lesions in patients with metastatic CRPC.
    [FibroGen, Inc.]

    Press Release
    FEATURED EVENT

    Gene and Cell-Based Therapies: Progress in Clinical Translation

    November 2-4, 2025
    Los Angeles, California, United States

    > See All Events

    JOB OPPORTUNITIES

    Clinical Research Fellow – Prostate Cancer

    University College London – London, England, United Kingdom

    Postdoctoral Associate – Genitourinary Cancers

    University of Miami Desai Sethi Urology Institute – Miami, Florida, United States

    Research Associate in AI and Medical Imaging – Prostate Cancer

    King’s College London – London, England, United States

    Assistant/Associate/Senior Scientist – Cancer Research

    Henry Ford Health + Michigan State – Detroit, Michigan, United States

    Senior Research Associate – Prostate Cancer Health Services Research

    University of Bristol – Bristol, England, United Kingdom

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2